Cookies on the Milliman Website

Our site uses cookies so that we can remember you and understand how you and other visitors use the site, By using our site you agree to our use of cookies. You can find information on what cookies are and how we use them in our privacy policy.

Genetic testing in England: ROI, cost-effectiveness analysis, or both to evaluate intervention

In healthcare, return on investment (ROI) can be used to measure the effectiveness of various disease management programmes. ROI provides a framework to help determine whether additional funds should be allocated to a particular activity or alternatively, whether these funds should be withdrawn and allocated elsewhere. The rapid uptake of genetic testing within the National Health Service (NHS) and current debate around genetics make evaluating tailored interventions increasingly more relevant to ensure an efficient use of NHS spend.

Careers

Insight

For more than seven decades, Milliman has combined technical
expertise with business acumen to create elegant solutions
for our clients.

Today, we are helping companies take on
some of the world's most critical and complex issues, including retirement
funding and healthcare financing, risk management and regulatory compliance,
data analytics and business transformation.